Last reviewed · How we verify
candsartan cilexetil — Competitive Intelligence Brief
phase 3
Small molecule
Live · refreshed every 30 min
Target snapshot
candsartan cilexetil (candsartan cilexetil) — AstraZeneca. Blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction and aldosterone release to lower blood pressure.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| candsartan cilexetil TARGET | candsartan cilexetil | AstraZeneca | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- candsartan cilexetil CI watch — RSS
- candsartan cilexetil CI watch — Atom
- candsartan cilexetil CI watch — JSON
- candsartan cilexetil alone — RSS
Cite this brief
Drug Landscape (2026). candsartan cilexetil — Competitive Intelligence Brief. https://druglandscape.com/ci/candsartan-cilexetil. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing